Literature DB >> 16134825

Morphological manifestations of heart remodeling in anthracycline-induced dilated cardiomyopathy.

E L Lushnikova1, M G Klinnikova, O P Molodykh, L M Nepomnyashchikh.   

Abstract

The morphogenesis of anthracycline-induced dilated cardiomyopathy was studied after single sublethal dose of doxorubicin. Cardiomyocyte depopulation (up to 27%) and decrease in their regeneratory plastic reactions were the main mechanisms of cardiac failure development after anthracycline (doxorubicin) treatment, determining the type of heart remodeling by the dilatation variant. Cardiomyocyte elimination and atrophy during the development of anthracycline-induced regeneratory plastic cardiac insufficiency were paralleled by hypertrophy of remaining cardiomyocytes and diffuse and small focal sclerosis of the myocardium, which could be regarded as a correlated compensatory reaction of the connective tissue to the decrease in the number of muscle fibers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16134825     DOI: 10.1007/s10517-005-0138-0

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  5 in total

1.  Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific.

Authors:  Gonçalo C Pereira; Susana P Pereira; Claudia V Pereira; José A Lumini; José Magalhães; António Ascensão; Maria S Santos; António J Moreno; Paulo J Oliveira
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

2.  Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and Hypertrophy.

Authors:  Wawaimuli Arozal; Flori R Sari; Kenichi Watanabe; Somasundaram Arumugam; Punniyakoti T Veeraveedu; Meilei Ma; Rajarajan A Thandavarayan; Vijayakumar Sukumaran; Arun Prasath Lakshmanan; Yoshiyasu Kobayashi; Sayaka Mito; Vivian Soetikno; Kenji Suzuki
Journal:  ISRN Pharmacol       Date:  2011-04-14

Review 3.  Reversal of Doxorubicin-induced Cardiotoxicity by Using Phytotherapy: A Review.

Authors:  Azar Hosseini; Amirhossein Sahebkar
Journal:  J Pharmacopuncture       Date:  2017-08-22

4.  Molecular pathogenetic mechanisms and new therapeutic perspectives in anthracycline-induced cardiomyopathy.

Authors:  Giuseppe Distefano
Journal:  Ital J Pediatr       Date:  2009-11-20       Impact factor: 2.638

5.  Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines.

Authors:  Olga H Toro-Salazar; Ji Hyun Lee; Kia N Zellars; Paige E Perreault; Kathryn C Mason; Zhu Wang; Kan N Hor; Eileen Gillan; Caroline J Zeiss; Daniel M Gatti; Brooke T Davey; Shelby Kutty; Bruce T Liang; Francis G Spinale
Journal:  Cardiooncology       Date:  2018-05-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.